BioNTech
BiotechMainz, Germany, Germany · Est. 2008 · 5,200 employees
BioNTech is a German biotechnology company that develops mRNA-based therapeutics and vaccines for cancer and infectious diseases.
27
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
22
Indications↗
Distinct diseases across all programs
100
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
27 drugs in development
Phase 31
Phase 213
Phase 17
Preclinical12
By Therapeutic Area
top 2
Oncology
2172%
Infectious Disease
621%
R&D Momentum
65/100
Pipeline Velocity
41/100
Trial Completion Rate
80/100
Pipeline Concentration
57/100
Pipeline Freshness
84/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
Activity
Recent Activity
Last 14 days
Sep 19, 2026
Recruiting
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
Sep 18, 2026
Recruiting
A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer
Sep 18, 2026
Recruiting
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease
Sep 18, 2026
Recruiting
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer
Sep 16, 2026
Active, not recruiting
A First-in-Human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of BNT314 as Monotherapy in Patients With Advanced Malignant Solid Tumors
Sep 16, 2026
Completed
A Randomized, Partially Observer-blind, Dose-escalation, Phase I/II Trial Evaluating the Safety and Immunogenicity of Investigational RNA-based Mpox Vaccine Candidates
Sep 15, 2026
Active, not recruiting
A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer
Sep 10, 2026
Recruiting
A Phase I/II, First-in-human, Open-label Trial of the Safety, Efficacy, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Participants With Advanced Solid Tumors
Sep 9, 2026
Active, not recruiting
An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1
3 more events
Sep 5, 2026TrialA Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer
Sep 3, 2026TrialA Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors
Sep 2, 2026TrialA Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer
Details
Company Info
Company Overview
$26.0B
Mkt Cap
$18.0B
Revenue
—
Cash
CEOUgur Sahin
Founded2008
Employees5,200
HQMainz, Germany, Germany
Websitebiontech.de
LinkedInCompany Page
Therapeutic Focus
oncologyinfectious diseasesimmunotherapypersonalized medicine
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Infectious Disease(6 drugs)
—
2
3
1
—
Infectious Disease(6 drugs)
Oncology(21 drugs)
11
5
10
—
—
Oncology(21 drugs)
Unknown / Other(2 drugs)
2
—
—
—
—
Unknown / Other(2 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)